Bristol-Myers Squibb Sponsors the Addario Lung Cancer Foundation’s “Simply the Best” Dinner and Gala

For further information or inquiries, please contact:

Julia Spiess Lewis
Perry Communications Group
[email protected]

Bristol-Myers Squibb Sponsors the Addario Lung Cancer Foundation’s “Simply the Best” Dinner and Gala
ALCF’s Tenth Annual Fundraiser Celebrates Lung Cancer Survivors and Honors the Dedicated Researchers Fighting for Improved Treatments

SAN CARLOS, Calif. (November 10, 2015) — The Bonnie J. Addario Lung Cancer Foundation (ALCF) today announced Bristol-Myers Squibb (BMS) as a title sponsor for its tenth annual “Simply the Best” Dinner and Gala. Through this sponsorship, the organization is supporting and celebrating lung cancer survivors for their hope and determination and the researchers who dedicate their lives to developing improved treatment options for lung cancer patients. The Gala is in San Francisco, Calif. on November 14, 2015.

“Bristol-Myers Squibb’s immuno-oncology research has revolutionized the approach to lung cancer treatment,” said Bonnie J. Addario, 10-year lung cancer survivor and founder of the ALCF. “Lung cancer is the most commonly diagnosed cancer and has one of the highest mortality rates. There is significant need for treatment options that benefit patients and BMS is leading the way into a new and hopeful era for lung cancer patients. We are honored to have their support and partnership at this event.”

Immuno-oncology is a new approach that uses a patient’s immune system to help fight cancer. Bristol-Myers Squibb received FDA approval for the first immuno-oncology medication for patients with previously treated advanced non-small cell lung cancer (NSCLC), representing an exciting development for lung cancer patients. NSCLC is one of the most common types of lung cancer and accounts for more than 85 percent of all diagnoses.

“We are honored to support ALCF and the role they play in providing critical education and care for lung cancer patients throughout the world,” said Teresa Bitetti, senior vice president, Oncology, Bristol-Myers Squibb. “Like ALCF, we have a strong commitment to supporting the cancer community, spanning more than 50 years. We look forward to continued collaboration during this exciting time of progress and innovation, with a shared focus on helping to improve survival for people living with lung cancer.”

While the research into new treatment for lung cancer has improved, lung cancer still accounts for more cancer deaths than breast, colon and prostate cancer combined. In 2015, an expected 221,200 new lung cancer diagnoses in the U.S. will lead to nearly 158,040 Americans to die of the disease.1

For more information about the “Simply the Best” Dinner and Gala visit:

For more information about the ALCF please visit or follow us on Facebook or Twitter.

About the Bonnie J. Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation’s goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. The ALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised nearly $25 million for lung cancer research and related programs.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit, or follow us on Twitter at

1 American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015.